Larimar Therapeutics Secures FDA Breakthrough Designation, Eyes June 2026 BLA Submission
The FDA granted Breakthrough Therapy Designation to Larimar Therapeutics’ nomlabofusp for Friedreich’s ataxia, covering adult and pediatric patients based on open-label study data. The company expects Q2 2026 topline data and targets a June 2026 BLA submission, with global Phase 3 dosing planned mid-2026.
1. FDA Grants Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy Designation to nomlabofusp for Friedreich’s ataxia, covering both adult and pediatric patients and supporting the use of skin frataxin levels as a surrogate endpoint. This status is intended to expedite development and regulatory review for therapies showing potential to improve outcomes over existing treatments.
2. Clinical Development and Regulatory Timeline
Larimar plans to report topline results from its START program open-label study in Q2 2026 and file a Biologics License Application in June 2026. A global Phase 3 trial will begin patient screening in Q2, with first dosing expected mid-2026 and a U.S. launch targeted for H1 2027 upon approval.
3. Technical Indicators Signal Strong Momentum
Shares jumped over 30% to $3.70, trading 13.6% above their 20-day simple moving average and 7.4% above their 50-day SMA, with key resistance at $4.00 and support at $3.50. An RSI of 33.78 and a MACD below its signal line suggest mixed technical momentum despite the sharp rally.